NCT03302403 - Clinical Study of Redirected Autologous T Cells With a Chimeric Antigen Receptor in Patients With Malignant Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 29, 2017

Primary Completion Date

December 12, 2020

Study Completion Date

December 12, 2023

Conditions

B Cell LymphomaB Cell LeukemiaMyelomaHepatocellular CarcinomaPancreatic CarcinomaAdenocarcinoma of Esophagogastric Junction

Interventions

GENETIC

CAR-CD19 T cell

"Self-controlled dose escalation and classic 3+3 dose escalation will be applied."

GENETIC

CAR-BCMA T cell

"Self-controlled dose escalation and classic 3+3 dose escalation will be applied."

GENETIC

CAR-GPC3 T cell

"Self-controlled dose escalation and classic 3+3 dose escalation will be applied."

GENETIC

CAR-CLD18 T cell

"Self-controlled dose escalation and classic 3+3 dose escalation will be applied."

DRUG

Fludarabine

Fludarabine is used for lymphodepletion.

DRUG

Cyclophosphamide

Cyclophosphamide is used for lymphodepletion.

Trial Locations (1)

First Affiliated Hospital of Wenzhou Medical University, Wenzhou